Benzinga

Benzinga Korea 한국

Benzinga

Benzinga Korea 한국

Benzinga

Benzinga Korea 한국
금요일, 9월 04

Harvard Bioscience Inc

HBIONASDAQ
Trade with Public
Trade with Public
$8.02
0.020.25%
가까이에: Sep 4, 5:00 PM EST
$8.18
0.162%
시간외: Sep 1, 7:50 PM EST
개요뉴스실적 전망이벤트목표가재무심리지분 현황비교주식 보고서

Harvard Bioscience Analyst Price Targets

Wall Street analyst price targets and consensus rating for Harvard Bioscience (HBIO).

Price Target Range — 5 Quarters

Analyst Consensus

Consensus RatingSpeculative BuyAvg. Consensus PT$5Upside to Avg. PT-35.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 12, 2026BenchmarkBruce D. JacksonPT RaiseSpeculative Buy$6→$8
Mar 16, 2026BenchmarkBruce D. JacksonPT RaiseSpeculative Buy$1→$6
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Benchmark Maintains Speculative Buy on Harvard Bioscience, Raises Price Target to $7.5

Benchmark analyst Bruce D. Jackson maintains Harvard Bioscience (NASDAQ:HBIO) with a Speculative Buy and raises the price target from $6 to $7.5.
Benzinga Newsdesk

PRO
Benchmark Maintains Speculative Buy on Harvard Bioscience, Raises Price Target to $6

Benchmark analyst Bruce D. Jackson maintains Harvard Bioscience (NASDAQ:HBIO) with a Speculative Buy and raises the price target from $0.6 to $6.
Benzinga Newsdesk

PRO
Benchmark Maintains Speculative Buy on Harvard Bioscience, Lowers Price Target to $0.6

Benchmark analyst Bruce D. Jackson maintains Harvard Bioscience (NASDAQ:HBIO) with a Speculative Buy and lowers the price target from $2 to $0.6.
Benzinga Newsdesk

PRO
Benchmark Maintains Speculative Buy on Harvard Bioscience, Lowers Price Target to $2

Benchmark analyst Bruce D. Jackson maintains Harvard Bioscience (NASDAQ:HBIO) with a Speculative Buy and lowers the price target from $3 to $2.
Benzinga Newsdesk

PRO
Benchmark Maintains Speculative Buy on Harvard Bioscience, Lowers Price Target to $3

Benchmark analyst Bruce Jackson maintains Harvard Bioscience (NASDAQ:HBIO) with a Speculative Buy and lowers the price target from $4.5 to $3.
Benzinga Newsdesk

PRO
Keybanc Downgrades Harvard Bioscience to Sector Weight

Keybanc analyst Paul Knight downgrades Harvard Bioscience (NASDAQ:HBIO) from Overweight to Sector Weight.
Benzinga Newsdesk

데이터 및 API: Benzinga API · 주식 뉴스 API · 애널리스트 등급 API · 회사 로고 API

시장 데이터 제공 Benzinga API

Benzinga

Benzinga Korea 한국

뉴스

파트너 / 기고자

벤징가 글로벌

© 2026 Benzinga | All Rights Reserved